Trial · NCT00349973
Clinical Trial of Dipyridamole in Schizophrenia
NCT00349973, Not applicable, Completed, University of Maryland, Baltimore; results first posted 2018-12-10
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Clinical Trial of Dipyridamole in Schizophrenia. Trials, record NCT00349973. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00349973
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Clinical Trial of Dipyridamole in Schizophrenia
- NCT number
- NCT00349973
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 29 participants, actual
- Lead sponsor
- University of Maryland, Baltimore
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder
- Interventions
- Dipyridamole, Olanzapine
- First posted
- 2006-07-10
- Last updated
- 2019-11-04
- Results first posted
- 2018-12-10
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Positive Symptoms by Treatment Assignment | Baseline and follow-up | The Brief Psychiatric Rating Scale (BPRS) consists of 20 items, with 6 of these items used to assess positive symptom change. The BPRS positive symptom items are: somatic concern, conceptual disorganization, hostility, suspiciousness, hallucinatory behavior, and unusual thought content. Each scale ranges from "1=Not Present" to "7=Very Severe". A higher score indicates a more severe positive symptom rating. |
| Primary | Change in Negative Symptoms by Treatment Assignment | Baseline and Follow-Up | The Scale for the Assessment of Negative Symptoms (SANS) total score, minus the global items, inappropriate affect, poverty of content of speech, and attention items, used to measure negative symptoms. Mean SANS total score by treatment and week. SANS total score range = 0-85. Higher scores indicate more severe negative symptoms. |
| Primary | The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) | Baseline and Follow-Up | The RBANS is a brief, individually administered test designed to evaluate neuropsychological status of adults, ages 20-89. The 12 subtests measure attention, language, visuospatial/constructional abilities, and immediate and delayed memory. The raw scores from the subtests are scaled together to create index scores, and these are summed for conversion to a total scale score. Higher score equals a better outcome. The total index score range for the RBANS is 40-160. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Positive Symptoms by Treatment Assignment | Baseline and follow-up | Participants completing the BPRS assessment. | units on a scale | MEAN |
| PRIMARY | Change in Negative Symptoms by Treatment Assignment | Baseline and Follow-Up | Participants completing SANS assessment. | units on a scale | MEAN |
| PRIMARY | The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) | Baseline and Follow-Up | Participants completing cognitive testing. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Positive Symptoms by Treatment Assignment | Dipyridamole | Baseline - Somatic Concern | 2.222 | Standard Deviation 1.716 | units on a scale |
| Change in Positive Symptoms by Treatment Assignment | Olanzapine | Baseline - Somatic Concern | 1.400 | Standard Deviation 0.548 | units on a scale |
| Change in Positive Symptoms by Treatment Assignment | Dipyridamole | Follow-Up - Somatic Concern | 1.60 | Standard Deviation 1.34 | units on a scale |
| Change in Positive Symptoms by Treatment Assignment | Olanzapine | Follow-Up - Somatic Concern | 1.00 | Standard Deviation 0.00 | units on a scale |
| Change in Positive Symptoms by Treatment Assignment | Dipyridamole | Baseline - Conceptual Disorganization | 2.667 | Standard Deviation 1.225 | units on a scale |
| Change in Positive Symptoms by Treatment Assignment | Olanzapine | Baseline - Conceptual Disorganization | 2.600 | Standard Deviation 0.894 | units on a scale |
| Change in Positive Symptoms by Treatment Assignment | Dipyridamole | Follow-Up - Conceptual Disorganization | 2.00 | Standard Deviation 1.41 | units on a scale |
| Change in Positive Symptoms by Treatment Assignment | Olanzapine | Follow-Up - Conceptual Disorganization | 2.00 | Standard Deviation 1.41 | units on a scale |
| Change in Positive Symptoms by Treatment Assignment | Dipyridamole | Baseline - Hostility | 1.222 | Standard Deviation 0.667 | units on a scale |
| Change in Positive Symptoms by Treatment Assignment | Olanzapine | Baseline - Hostility | 1.200 | Standard Deviation 0.447 | units on a scale |
1 to 10 of 32Source ClinicalTrials.gov
See all 32 results by groupParticipant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dipyridamole | 12 | |
| Overall Study | STARTED | Olanzapine | 8 | |
| Overall Study | COMPLETED | Dipyridamole | 8 | |
| Overall Study | COMPLETED | Olanzapine | 5 | |
| Overall Study | NOT COMPLETED | Dipyridamole | 4 | |
| Overall Study | NOT COMPLETED | Olanzapine | 3 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dipyridamole | ||
| Total, all-cause mortality | Olanzapine | ||
| Total, other adverse events | Dipyridamole | 0 | 12 |
| Total, other adverse events | Olanzapine | 0 | 8 |
| Total, serious adverse events | Dipyridamole | 0 | 12 |
| Total, serious adverse events | Olanzapine | 0 | 8 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Dipyridamole vs Olanzapine: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00349973
GET https://conductscience.org/api/trials/v1/NCT00349973/results?page=2